[A22-28] Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 16.05.2022
Project no.:
A22-28
Commission:
Commission awarded on 15.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy
Result of dossier assessment:
- After first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven.
- After first-line therapy with cytotoxic chemotherapy: added benefit not proven.
- After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-06 | Sotorasib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |